

# 1 **Role of IL-23 neutralization in psoriasis – insights from a** 2 **mechanistic PK/PD model and meta-analysis of clinical data**

3 Author: Georgi I. Kapitanov

4 Affiliation: BioMedicine Design, Worldwide Research and Development, Pfizer Inc., Cambridge,  
5 Massachusetts, 02139, USA

6 Correspondence: [georgi.kapitanov@pfizer.com](mailto:georgi.kapitanov@pfizer.com)

7

## 8 **Abstract**

9 Blocking of IL-23 has shown a profound effect on patient outcomes in psoriasis. The current IL-  
10 23 binding monoclonal antibodies show differences in dosing regimens, pharmacokinetics,  
11 affinity for the target, and efficacy outcomes in the clinic. The goal of the current work is to use a  
12 mechanistic pharmacokinetics/pharmacodynamics mathematical model to estimate projected  
13 free IL-23 neutralization for the different therapeutic molecules and connect it to clinical efficacy  
14 outcomes. The meta-analysis indicates a sigmoid-like relationship and suggests that the best  
15 current anti-IL23 antibodies are close to saturating the efficacy that can be achieved by this  
16 pathway in psoriasis.

17 Keywords: Interleukin-23, PKPD, meta-analysis, psoriasis, PASI scores

## 18 **Introduction**

19 Cytokines are soluble signaling proteins that participate in many inflammatory processes and  
20 can initiate and propagate a variety of inflammatory indications and autoimmune diseases –  
21 rheumatoid arthritis, atopic dermatitis, inflammatory bowel disease, and psoriasis, among others  
22 (1-4). Using therapeutic antibodies that bind directly to the cytokine or its receptor on immune  
23 cells to neutralize cytokine-mediated signaling, has shown to be an effective strategy for  
24 mitigating these diseases. Some examples include adalimumab (Humira) and infliximab  
25 (Remicade), anti-TNF $\alpha$  monoclonal antibodies (mAbs) that have been approved for treatment in  
26 psoriasis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) (5); dupilumab  
27 (Dupixent), a mAb which modulates interleukin (IL-)4 and IL-13 signaling by blocking IL-4  
28 receptor  $\alpha$  (IL-4R  $\alpha$ ) and has been approved for atopic dermatitis and asthma (6, 7);  
29 secukinumab (Cosentyx), an anti-IL17A mAb approved for psoriasis (8); tocilizumab (Actemra),  
30 an anti-IL-6R mAb approved for RA (9).

31

32 Psoriasis is an auto-immune disease characterized by dry, scaly skin patches that affects over  
33 100 million people worldwide. Common co-morbidities are diabetes, heart disease and  
34 depression (10). Modulating the Th17 pathway has had a profound effect on mediating the  
35 pathogenesis of psoriasis, both through blocking IL-23 and through blocking IL-17A (8, 11-14).  
36 Some of the current biologic therapeutics on the market achieve clear to almost clear skin in

37 more than 70% of patients (15-18), which allows for a small margin of improvement for any  
38 future therapeutics.

39  
40 IL-23 is a heterodimeric cytokine comprising two subunits, IL12p40 (shared with IL-12) and  
41 IL23p19. It is secreted by antigen-presenting cells and keratinocytes and plays a role in the  
42 proliferation of Th17 cells, which are implicated in chronic inflammation associated with  
43 psoriasis (8, 11-14). Ustekinumab was the first approved anti-IL-23 therapeutic, targeting the  
44 IL12p40 subunit of IL-23, hence blocking both IL-12 and IL-23 activity. Discoveries suggesting a  
45 key role for IL-23 in the pathophysiology of psoriasis led to follow on therapeutics that solely  
46 target the IL23p19 subunit of IL-23, which spares IL-12 signaling (19).

47  
48 The current work attempts to shed light on the role of blocking IL-23 in psoriasis through a  
49 mechanistic model of the pharmacokinetic/pharmacodynamic (PK/PD) interaction between the  
50 IL-23 blockers and IL-23. The model quantifies the effect of projected IL-23 neutralization on  
51 clinical endpoints in psoriasis. This modeling effort has implications for the future development  
52 of IL-23 blockers in psoriasis: using PK data and affinity to IL-23, one can project the efficacy  
53 that would be observed in the clinic at a particular dosing regimen.

## 54 Methods

### 55 PK/PD model set up

56 A two-compartment model that incorporates drug:target binding interactions in the central  
57 (plasma) compartment was used. Interactions of anti-IL12p40 drugs (ustekinumab and  
58 briakinumab) with only IL-23 were considered; binding/unbinding to IL12p40 monomer and  
59 homodimer, as well as IL-12, were ignored. The model scheme can be seen in Figure 1 and the  
60 model equations are described in **Error! Reference source not found.**, where  $D_P$ ,  $T$ , and  
61  $C$  represent the concentrations in plasma of free drug, free IL-23, and drug-target complex,  
62 respectively.  $D_T$  is the drug concentration in the peripheral tissue compartment and  $D_D$  is the  
63 drug in the subcutaneous depot compartment.  $Dose(t)$  is the dose, which is administered  
64 subcutaneously at a certain interval. Target synthesis and elimination are assumed only in the  
65 Central compartment.

66

### 67 Equation 1


$$\begin{aligned} \frac{dD_D}{dt} &= Dose(t) - k_a D_D \\ \frac{dD_P}{dt} &= k_a F_{bio} D_D + k_{tp} D_T \frac{V_T}{V_P} - k_{pt} D_P - k_{on} D_P T + k_{off} C - k_{el} D_P \\ \frac{dD_T}{dt} &= k_{pt} D_P \frac{V_P}{V_T} - k_{tp} D_T \\ \frac{dC}{dt} &= k_{on} D_P T - k_{off} C - k_{elC} C \\ \frac{dT}{dt} &= k_{syn} - k_{on} D_P T + k_{off} C - k_{degT} T \end{aligned} \quad \#($$

68

69

70 Table I: Definitions and common values of parameters used in the model contains a  
 71 description of the model parameters and common estimated values used in the model. Table II  
 72 contains the binding affinity and pharmacokinetic parameters used for each drug.

73



74

75 *Figure 1: Model Scheme for anti-IL23 mAbs. After subcutaneous administration, the antibody is*  
 76 *in the Central compartment (plasma) and can distribute back and forth to the Peripheral*  
 77 *compartment. IL-23 is synthesized and degraded endogenously in the Central compartment*  
 78 *only. Binding and unbinding of the mAb with IL-23 as well as the clearance of the drug:target*  
 79 *complex are restricted to the Central compartment.*

80

81 *Table I: Definitions and common values of parameters used in the model*

| Parameter | Description                          | Value         | Units |
|-----------|--------------------------------------|---------------|-------|
|           | Central compartment volume           | Drug specific | L     |
|           | Drug distributive clearance rate     | Drug specific | L/day |
|           | Drug elimination clearance rate      | Drug specific | L/day |
|           | Peripheral tissue volume             | Drug specific | L     |
|           | Rate of absorption post subcutaneous | Drug specific | 1/day |

|            | drug administration   |                  |                                 |
|------------|---|------------------|---------------------------------|
| $F_{bio}$  | Bioavailability post subcutaneous drug administration               | Drug specific    | dimensionless                   |
| $k_{on}$   | Drug-target concentration-dependent association rate                | 86.4 (20)        | $\text{nM}^{-1}\text{day}^{-1}$ |
| $K_D$      | Drug-target dissociation constant                                   | Drug specific    | nM                              |
| $k_{off}$  | First-order dissociation rate constant of antibody                  | $k_{on}K_D$      | 1/day                           |
| $k_{el}$   | Rate constant of drug elimination from plasma                       | $\frac{Cl}{V_P}$ | 1/day                           |
| $k_{pt}$   | Rate constant of drug distribution from plasma to peripheral tissue | $\frac{Q}{V_P}$  | 1/day                           |
| $k_{tp}$   | Rate constant of drug distribution from peripheral tissue to plasma | $\frac{Q}{V_T}$  | 1/day                           |
| $k_{degT}$ | Rate constant of target elimination from plasma                     | 4.16 (21)        | 1/day                           |
| $k_{syn}$  | Zero order target synthesis rate in SoA                             | $k_{degT}T(0)$   | nM/day                          |
| $k_{elC}$  | Rate constant of complex elimination from plasma                    | $k_{el}$         | 1/day                           |

82  
 83 Target neutralization was calculated as  $TC = 1 - T/T(0)$ . The average target neutralization at a  
 84 time point  $t_p$  was calculated as  $TC_{ave} = \int_0^{t_p} TC(t)dt / t_p$  or, similarly to standard PK notation,  
 85 target neutralization  $AUC_{t_p}/t_p$ .  $T(0)$  is 0.7 pM (22) and IL-23 half-life is fixed at 4 h (21).

86 *Table II: Modeling parameters for anti-IL-23 mAbs*

87

| <b>Drug</b>      | <b>Ustekinumab (23)</b> | <b>Briakinumab (24)*</b> | <b>Guselkumab (25)*</b> | <b>Risankizumab (26)</b> | <b>Tildrakizumab (27)*</b> |
|------------------|-------------------------|--------------------------|-------------------------|--------------------------|----------------------------|
| <b>Parameter</b> |                         |                          |                         |                          |                            |
| $V_p$ , L        | 3.0                     | 3.0 (0.049)              | 3.1 (0.098)             | 5.7                      | 2.3 (0.031)                |
| $V_T$ , L        | 1.4                     | 3.5 (1.3)                | 3.9 (0.94)              | 3.4                      | 2.7 (0.12)                 |
| Q, L/day         | 0.16                    | 0.81 (0.14)              | 0.89 (0.27)             | 0.33                     | 1.3 (0.074)                |
| Cl, L/day        | 0.19                    | 0.74 (0.093)             | 0.30 (0.047)            | 0.30                     | 0.15 (0.0044)              |
| $k_a$ , 1/day    | 0.14                    | 0.24 (0.086)             | 0.31 (0.23)             | 0.18                     | 0.30 (0.059)               |
| $F_{bio}$ , %    | 87                      | 41 (8.8)                 | 42 (16)                 | 72                       | 79 (7.3)                   |
| $K_D$ , pM       | 120 (28)                | 100 (24)                 | 3 **                    | 1 (29)                   | 300 (30)                   |

88 \* Mean reported data were digitized and fit to a two-compartment PK model. Mean parameter fit results are reported and used in the modeling,  
 89 standard errors in parenthesis). Average human bodyweight assumed to be 70 kg. Fits were performed using MATLAB Simbiology.

90 \*\* FDA BLA document

## 91 Data collection and analysis



92 The efficacy endpoints chosen were % of patients who achieved a certain % reduction in  
 93 Psoriasis Area and Severity Index (i.e. PASI 75 refers to % of patients who achieved a 75%  
 94 reduction in their PASI score). Data from available clinical trials was collated, efficacy endpoints  
 95 (PASI 75, PASI 90, and PASI 100) were collected where available, and number of patients in  
 96 each trial and cohort noted. Clinical data combined psoriasis and plaque psoriasis data and  
 97 comprises four studies for ustekinumab (Phase (Ph) 2 (31) and Ph3 Accept (32) and Phoenix 1  
 98 & 2 (33, 34)), two studies for briakinumab (Ph2 (35) and Ph3 (36, 37)), five studies for  
 99 guselkumab (Ph1 (38), Ph2 (39, 40), Ph3 VOYAGE 1 & 2 (18, 39), and Ph3 ECLIPSE (41))  
 100 three studies for risankizumab (Ph2 (29) and Ph3 ULTIMMA 1 & 2 (15), ustekinumab data from  
 101 these studies were excluded because it was not dose-separated and results were consistent  
 102 with already available data), and three studies for tildrakizumab (Ph2b (30) and Ph3  
 103 reSURFACE 1 & 2 (42)).

104 The final efficacy readout used in the model was done on an intent-to-treat basis and placebo  
 105 corrected. If a placebo group was switched to drug administration, they were assumed to be a  
 106 different cohort and their target neutralization estimated separately. If there was no available  
 107 placebo data to correct efficacy at a particular time point or study, the nearest time point  
 108 placebo efficacy read out was assumed to carry forward or the placebo efficacy read out from  
 109 an equivalent phase study with the same drug was used.

110 Based on dosing regimens, average IL-23 neutralization was projected at the same time points  
 111 at which efficacy data was collated. A visual description with an example can be seen in Figure  
 112 2. All efficacy results, the associated IL-23 neutralization, and the number of patients were  
 113 pooled. A sigmoid curve with domain 0 to 1 was fit with IL-23 neutralization as independent  
 114 variable and efficacy as dependent variable (Equation 2), each point in the meta-analysis  
 115 weighted by the number of patients in the cohort from which the endpoint was collected. All  
 116 model construction and fits were done in MATLAB.

117 Equation 2:  $E$  is PASI 75/90/100,  $E_{max}$  is the maximum efficacy achieved at 100% suppression  
118 of IL-23,  $h$  is an inflexion-related parameter,  $TN$  is the projected IL-23 target neutralization in  
119 %, and  $h$  is a Hill-like power coefficient.

120 Figure 2: Steps in preparing the data for analysis. Step 1 (top): Based on PK and KD data for  
121 the molecule and dosing regimen in study cohorts, a prediction of IL-23 neutralization ( ) is  
122 generated (solid blue line). Average target neutralization ( ) is calculated from the  
123 prediction (dotted blue line). Efficacy endpoint score at particular time points are collated (open  
124 orange circles). The meta-analysis is based on projected average IL-23 neutralization in plasma  
125 and efficacy endpoints (bottom figure). The example presented is from ustekinumab Phase 3  
126 PHOENIX 1&2 studies, where the dosing regimen is 45 mg subcutaneously every four weeks  
127 for two doses and every twelve weeks afterwards. PASI 75 endpoints were collected at week 12  
128 and week 28. Two circles are shown at each graph – one for PHOENIX 1 and one for PHOENIX  
129 2 results.



130

131

132

## 133 Results

134 The parameter value for  $E_x$  was consistently fit to 1 for all efficacy endpoints, therefore is fixed  
135 at 1. This rewrites Equation 2 as  $E = E_{max} * 2 * (TN/100)^h / ((TN/100)^h + 1)$ , which  
136 reduces the fitting to parameters  $h$  and  $E_{max}$ .

137 The model captures a trend of increased efficacy with projected increase of IL-23 neutralization  
138 but does not fully account for the variability in the efficacy results. The parameter estimates are  
139 in Table III. Given the  $E_{max}$  values, with full neutralization of IL-23 one would expect 78% of  
140 patients to experience 75% reduction in PASI score, 67% of patients to experience 90%  
141 reduction, and 42% to achieve full reduction of their PASI score. From the equation for  $E$ , one  
142 can derive a value for  $TN50$ , i.e. the target neutralization of IL-23 at which 50% of the maximum  
143 efficacy endpoint is projected to be achieved. With  $E_x$  fixed at 1,  $TN50 = \left(\frac{1}{3}\right)^{1/h}$ . The  $TN50$   
144 values are reported in Table IV. For example,  $TN50$  PASI 100 is 76%, which indicates that in  
145 order to achieve PASI 100 of 21% (half of  $E_{max}$  PASI 100), an IL-23 blocker would need to  
146 neutralize 76% of plasma IL-23.

147 The confidence intervals around  $E_{max}$  increase with the PASI reduction needed to be achieved,  
148 which is expected since there would be many intra-patient factors that may affect the  
149 appearance of full or completely full clearance of skin and that would increase the variability of  
150 outcome.

151 The  $TN50$  values also increase with PASI score reduction, which is also expected – it is harder  
152 to achieve PASI 90 than PASI 75, for example. This also leads to saturation of the efficacy  
153 responses at lower IL-23 neutralization for lower level of efficacy response. A visual check on  
154 Figure 3 A shows that ~95% IL-23 neutralization saturates the PASI 75 response rate, B shows  
155 that ~99% IL-23 neutralization saturates the PASI 90 response rate, and C indicates that ~  
156 99.5% IL-23 neutralization saturates the PASI 100 response rate. Therefore, in order to  
157 differentiate from competitors, a new molecule needs to show efficacy at the harder to achieve  
158 endpoint. This conclusion is corroborated by the difference between earlier clinical trials where  
159 PASI 75 was enough to show differentiation (32, 40) and the more recent head-to-head trials  
160 where PASI 90 has become a primary endpoint (16, 39, 41).

161

*Table III: Parameter fit results*

| Parameter          | Value ( 95% CI)    | SE   |
|--------------------|--------------------|------|
| $E_{max}$ PASI 75  | 77.9 (75.4 – 80.3) | 1.2  |
| $E_{max}$ PASI 90  | 67.3 (63.6 – 71.1) | 1.9  |
| $E_{max}$ PASI 100 | 41.5 (37.1 – 45.9) | 2.2  |
| $h$ PASI75         | 1.06 (0.82 – 1.31) | 0.12 |
| $h$ PASI90         | 2.43 (1.93 – 2.94) | 0.25 |

|             |                    |      |
|-------------|--------------------|------|
| $h$ PASI100 | 4.09 (2.94 – 5.24) | 0.57 |
|-------------|--------------------|------|

162


163

*Table IV: TN50 calculations*


| Parameter    | Value  |
|--------------|--------|
| TN50 PASI75  | 35.5 % |
| TN50 PASI90  | 63.6 % |
| TN50 PASI100 | 76.4 % |

164


**A**



**B**



**C**



166 *Figure 3: A visual representation of the fit of Equation 2 to the collated data and projected IL-23*  
167 *neutralization. For presentation purposes, free remaining IL-23 is used on the x-axis. Projected*  
168 *free average IL-23 as % of baseline at different time points after drug administration is related to*  
169 *the average PASI 75 (A), 90 (B), and 100 (C) endpoints reported by the denoted drug at the*  
170 *same time point and the same doses using the function outlined in Equation 2. Open symbols*  
171 *denote data from Phase 3 trials, all others are from Phase 1 and 2 trials – the difference is used*  
172 *to indicate the weight of the points in the overall fit of the data. The percentage of free IL-23 was*  
173 *calculated as 100 times the ratio of simulated free IL-23 after drug administration and baseline*  
174 *IL-23. Results from the fits are reported in Table III.*

175

## 176 Discussion

177 Neutralization of IL-23 has proven to be an effective method for the treatment of psoriasis.  
178 Based on the analysis presented here, the greater the neutralization of IL-23, the better the  
179 efficacy. Ustekinumab (Stelara) was approved by the FDA in 2009, tildrakizumab (Ilumya) in  
180 2018, guselkumab (Tremfya) in 2017, and risankizumab (Skyrizi) in 2019. The latter two show a  
181 significant increase in affinity to IL-23 through binding to the IL23p19 unit and achieving  
182 significant improvement in efficacy over the other competitors in the class. At the time of  
183 preparation of this manuscript, another anti-IL23p19, mirikizumab, announced promising results  
184 in psoriasis (43), which were followed up with an announcement that establishes it as a highly  
185 competitive molecule (44). At the time, no full article, including pharmacokinetics data, had been  
186 published to the author's knowledge, hence mirikizumab data was omitted from the current  
187 analysis.

188 Similar comparative analysis of IL-23 neutralization among competitors was also done by  
189 Zhang et. al. (21). There are minor differences in drug:target interaction modeling between their  
190 approach and the present work. The goal in (21) was two-fold – to present results from  
191 recombinant IL-23 pharmacokinetics and to rank the molecules based on projected target  
192 neutralization in comparison to achieved PASI 100. Here the goal is to establish a general  
193 relationship between IL-23 neutralization and efficacy.

194 By targeting the IL12p40 subunit of IL-23, ustekinumab and briakinumab also target IL-12.  
195 Given the relatively low concentrations of cytokines in plasma, not explicitly accounting for the  
196 competition between IL-12 and IL-23 for binding to these therapeutics is reasonable. The  
197 method of analysis in the present work is not fit to statistically determine to what extent  
198 neutralizing IL-12 on top of IL-23 affects the efficacy read out for the two mAbs. However, their  
199 results are consistent with the overall behavior when combined with the rest of the available  
200 data. Therefore, based on the analysis conducted here, the efficacy achieved by both molecules  
201 appears due to blocking IL-23 only. Originally, ustekinumab and briakinumab were in  
202 development based on evidence for IL-12's role in psoriasis (19). Curiously, IL-23 was  
203 discovered right around the time ustekinumab's Investigational New Drug application with the  
204 Food and Drug Administration (FDA) was filed (FDA 75 FR 75678) and the therapeutic was  
205 being prepared for clinical trials (19). Further development of therapeutics targeting IL-23  
206 without interacting with IL-12, by blocking the IL23p19 subunit, indicates that in practice IL-12  
207 does not contribute significantly to the mitigation of psoriasis. Naturally, this hypothesis would

208 have to be evaluated by clinical trials of IL-12 blockers that do not interact with IL-23, which,  
209 given clinical and pre-clinical data and the current state of development of therapeutics for the  
210 disease, is unlikely (19). This is partially due to the effectiveness of anti-IL23p19 antibodies, as  
211 well as to the safety outcomes of briakinumab (45). Although Stelara is considered a highly safe  
212 therapeutic (46, 47), deaths in briakinumab clinical trials have pinpointed excessive blocking of  
213 IL12p40 as a potential concern, evidence for which is underwhelming and may be related to  
214 other factors (45). Furthermore, ustekinumab has been approved for Crohn's disease and  
215 ulcerative colitis, where blocking IL-12 along with IL-23 may have a more robust therapeutic  
216 role. More data from upcoming anti-IL23p19 blockers in IBD indications may shed more light on  
217 the role of each pathway in clinical efficacy.

218 Several points regarding the analysis performed here can be discussed further. The analysis is  
219 based on a 70 kg average patient, which is lower than the typical psoriasis patient. However,  
220 given that several compounds were analyzed and some of the PK parameters were taken from  
221 analysis in healthy volunteers as well as patients, it is unlikely that adding a bodyweight-based  
222 analysis would alter the overall results significantly. Early (induction), mid (around 6 months)  
223 and late (around 1 year) time points and projected IL-23 neutralization were analyzed together.  
224 Analysis was done with later time points removed and results did not differ substantially (data  
225 not shown), hence analysis including all time points is presented.

226 More variability was observed with the PASI 100 efficacy endpoint. The reasons may be several  
227 – 100% clear skin may be a more variable endpoint versus estimates of 90% or 75%  
228 improvement. Also, the variability at saturation comes from maintenance data from  
229 risankizumab and disappears when excluding late time points (results not shown). This result  
230 may be due to disease progression and another method of evaluation of IL-23 blockade that  
231 accounts for this may be a more robust predictor of efficacy.

232 While not the goal here, it would also be interesting to relate IL-23 neutralization to PASI change  
233 longitudinally. The longitudinal PASI data is sparse and not often presented in the literature.  
234 However, it is worth noting that an autoimmune disease like psoriasis can be effectively  
235 mitigated with a maintenance dosing regimen of every 8-12 weeks (48-51) versus another skin  
236 condition like atopic dermatitis, which appears to require a more frequent dosing of 2-4 weeks  
237 (52). This disparity may have implications for the target neutralization - efficacy relationship. On  
238 the other hand, while not providing superior efficacy, IL-23 blockers provide significantly  
239 improved dosing regimen compared to anti-IL17 blockers (53), so the difference in dosing  
240 regimens may be target-dependent as well. Analysis like the one done here can be performed  
241 to compare the anti-IL-17 blockers and propose a model-derived hypothesis for the difference in  
242 regimens.

243 The analysis conducted here also indicates that there is little room for improvement in outcomes  
244 for psoriasis patients with further neutralization of IL-23, given the saturating efficacy presented  
245 in Figure 3. However, the high level of IL-23 neutralization presented is partially the result of the  
246 target related parameters. Given the nature of interleukins and the consistently low protein  
247 levels detected in human plasma, it is unlikely that the baseline level of IL-23 would differ  
248 significantly from the concentration used here. However, the reference used to inform the rate of

249 IL-23 elimination is derived from cynomolgus monkey recombinant IL-23 PK study (21). All  
250 these factors may affect the endogenous turnover rate of IL-23 in humans. Given the already  
251 projected overall high neutralization, it is unlikely that the turnover in humans would be slower –  
252 this would only make the projected neutralization even higher and differentiation between the  
253 different molecules smaller, hence indicating that small differences in neutralization of the target  
254 lead to large differences in efficacy, the probability of which is low. However, higher turnover  
255 would mathematically result in faster IL-23 synthesis, which would decrease the level of  
256 neutralization. If significant, this would imply that there is further room for improvement in  
257 efficacy by increased blocking of IL-23. Given the reported very high affinities for risankizumab  
258 and guselkumab, the way to achieve this would likely be through applying even higher doses in  
259 psoriasis trials. Given the high efficacy of those two molecules at the current doses, this is  
260 unlikely to be tested in any robust manner in the near future.

261 The value of conducting modeling analyses like the currently presented one goes beyond  
262 comparison among molecules – for this purpose there are network meta-analyses of clinical  
263 data that utilize tools from pharmacometrics and statistics (53, 54). The model presented here  
264 can be used for informing future endeavors in the development of anti-IL-23 molecules for  
265 psoriasis but can also serve physicians for establishing a more robust confidence in superiority  
266 of one compound over another when head-to-head clinical data are lacking. Further, the model  
267 could also be used for projecting alternative dosing regimens for compounds for the purpose of  
268 improving efficacy better than a single compound exposure-response analysis because it  
269 includes a wider range of compounds and data. However, while the model can be potentially  
270 informative, real-world data would be needed to validate the projected efficacy and ensure the  
271 safety of the patients at these alternative regimens.

## 272 Conclusion

273 A mechanistic model of free IL-23 serum neutralization and analysis of its effect on efficacy  
274 endpoints in psoriasis using available data from clinical trials was conducted. The results  
275 indicate that the higher the level of IL-23 neutralization, the better the efficacy and conclude,  
276 based on the high projected IL-23 neutralization, that there is little room for further improvement  
277 in the treatment of psoriasis through this pathway.

## 278 Conflict of Interest

279 The author is an employee of Pfizer, Inc. The author declares no other competing interests for  
280 this work.

## 281 References

- 282
- 283 1. Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature  
284 cytokines in autoimmune and inflammatory diseases. *Cytokine*. 2015;74(1):5-17.
  - 285 2. Moudgil KD, Choubey D. Cytokines in Autoimmunity: Role in Induction, Regulation, and  
286 Treatment. *Journal of Interferon & Cytokine Research*. 2011;31(10):695-703.

- 287 3. Shachar I, Karin N. The dual roles of inflammatory cytokines and chemokines in the  
288 regulation of autoimmune diseases and their clinical implications. *Journal of Leukocyte Biology*.  
289 2013;93(1):51-61.
- 290 4. Feldmann M, Brennan FM, Maini R. Cytokines in Autoimmune Disorders. *International*  
291 *Reviews of Immunology*. 1998;17(1-4):217-28.
- 292 5. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and  
293 future. *Int Immunol*. 2015;27(1):55-62.
- 294 6. Rathinam KK, Abraham JJ, Vijayakumar TM. Dupilumab in the Treatment of Moderate to  
295 Severe Asthma: An Evidence-Based Review. *Current Therapeutic Research*. 2019;91:45-51.
- 296 7. Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the  
297 treatment of atopic diseases. *Human Vaccines & Immunotherapeutics*. 2019;15(9):2129-39.
- 298 8. Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease:  
299 pathogenetic and therapeutic implications. *Auto Immun Highlights*. 2014;5(1):9-19.
- 300 9. Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra).  
301 *Human vaccines & immunotherapeutics*. 2017;13(9):1972-88.
- 302 10. National Psoriasis Foundation. National Psoriasis Foundation - Statistics 2020 [Available  
303 from: <https://www.psoriasis.org/content/statistics>].
- 304 11. Chiu H-Y, Cheng Y-P, Tsai T-F. T helper type 17 in psoriasis: From basic immunology to  
305 clinical practice. *Dermatologica Sinica*. 2012;30(4):136-41.
- 306 12. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 Axis in the Immunopathogenesis  
307 of Psoriasis. *Journal of Investigative Dermatology*. 2009;129(6):1339-50.
- 308 13. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis:  
309 recent advances on IL-23 and Th17 cytokines. *Curr Rheumatol Rep*. 2007;9(6):461-7.
- 310 14. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the  
311 treatment of psoriatic arthritis and psoriasis. *Current Opinion in Rheumatology*. 2015;27(2).
- 312 15. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and  
313 safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2):  
314 results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled  
315 phase 3 trials. *Lancet (London, England)*. 2018;392(10148):650-61.
- 316 16. Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour J-P, et al.  
317 Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. *The New England*  
318 *journal of medicine*. 2017;376(16):1551-60.
- 319 17. Kaplon H, Reichert JM. Antibodies to watch in 2018. *MAbs*. 2018;10(2):183-203.
- 320 18. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and  
321 safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab  
322 for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and  
323 retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled  
324 VOYAGE 2 trial. *Journal of the American Academy of Dermatology*. 2017;76(3):418-31.
- 325 19. Teng MWL, Bowman EP, McElwee JJ, Smyth MJ, Casanova J-L, Cooper AM, et al. IL-  
326 12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory  
327 diseases. *Nature Medicine*. 2015;21(7):719-29.
- 328 20. Foote J, Eisen HN. Kinetic and affinity limits on antibodies produced during immune  
329 responses. *Proceedings of the National Academy of Sciences of the United States of America*.  
330 1995;92(5):1254-6.
- 331 21. Zhang T-T, Ma J, Durbin KR, Montavon T, Lacy SE, Jenkins GJ, et al. Determination of  
332 IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent  
333 Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies.  
334 *The AAPS Journal*. 2019;21(5):82.
- 335 22. Atwa MA, Emara AS, Youssef N, Bayoumy NM. Serum concentration of IL-17, IL-23 and  
336 TNF- $\alpha$  among patients with chronic spontaneous urticaria: association with disease activity and

- 337 autologous serum skin test. *Journal of the European Academy of Dermatology and*  
338 *Venereology*. 2014;28(4):469-74.
- 339 23. Xu Y, Hu C, Chen Y, Miao X, Adedokun OJ, Xu Z, et al. Population Pharmacokinetics  
340 and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to  
341 Severely Active Ulcerative Colitis. *The Journal of Clinical Pharmacology*. 2020;n/a(n/a).
- 342 24. Patent US20140079714A1.
- 343 25. Zhuang Y, Calderon C, Marciniak SJ, Jr., Bouman-Thio E, Szapary P, Yang T-Y, et al.  
344 First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy  
345 subjects and patients with moderate-to-severe psoriasis. *European journal of clinical*  
346 *pharmacology*. 2016;72(11):1303-10.
- 347 26. Suleiman AA, Khatri A, Minocha M, Othman AA. Population Pharmacokinetics of the  
348 Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses  
349 of Phase I and II Trials. *Clinical pharmacokinetics*. 2019;58(3):375-87.
- 350 27. Khalilieh S, Hodsman P, Xu C, Tzontcheva A, Glasgow S, Montgomery D.  
351 Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After  
352 Intravenous or Subcutaneous Administration in Healthy Subjects. *Basic & clinical pharmacology*  
353 *& toxicology*. 2018;123(3):294-300.
- 354 28. Luo J, Wu S-J, Lacy ER, Orlovsky Y, Baker A, Teplyakov A, et al. Structural Basis for  
355 the Dual Recognition of IL-12 and IL-23 by Ustekinumab. *Journal of Molecular Biology*.  
356 2010;402(5):797-812.
- 357 29. Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, et al. Anti-IL-23A  
358 mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy,  
359 pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind,  
360 placebo-controlled trial. *The Journal of allergy and clinical immunology*. 2015;136(1):116-24.e7.
- 361 30. Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-  
362 3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb  
363 randomized placebo-controlled trial. *The British journal of dermatology*. 2015;173(4):930-9.
- 364 31. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A Human  
365 Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis. *New England Journal of*  
366 *Medicine*. 2007;356(6):580-92.
- 367 32. Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al.  
368 Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. *New England*  
369 *Journal of Medicine*. 2010;362(2):118-28.
- 370 33. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and  
371 safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with  
372 psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX  
373 1). *The Lancet*. 2008;371(9625):1665-74.
- 374 34. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy  
375 and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with  
376 psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX  
377 2). *Lancet*. 2008;371(9625):1675-84.
- 378 35. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, et al. Safety and  
379 Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of  
380 Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Placebo-Controlled,  
381 Phase 2 Trial. *Archives of Dermatology*. 2008;144(2):200-7.
- 382 36. Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of  
383 briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque  
384 psoriasis. *British Journal of Dermatology*. 2011;165(3):652-60.
- 385 37. Reich K, Langley RG, Papp KA, Ortonne J-P, Unnebrink K, Kaul M, et al. A 52-week trial  
386 comparing briakinumab with methotrexate in patients with psoriasis. *The New England journal*  
387 *of medicine*. 2011;365(17):1586-96.

- 388 38. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al.  
389 Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients  
390 with moderate-to-severe psoriasis. *The Journal of allergy and clinical immunology*.  
391 2014;133(4):1032-40.
- 392 39. Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen Y-K, et al. Efficacy and  
393 safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab  
394 for the continuous treatment of patients with moderate to severe psoriasis: Results from the  
395 phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. *Journal of*  
396 *the American Academy of Dermatology*. 2017;76(3):405-17.
- 397 40. Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A Phase 2 Trial of  
398 Guselkumab versus Adalimumab for Plaque Psoriasis. *The New England journal of medicine*.  
399 2015;373(2):136-44.
- 400 41. Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab  
401 versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from  
402 a phase 3, randomised controlled trial. *The Lancet*. 2019;394(10201):831-9.
- 403 42. Reich K, Papp KA, Blauvelt A, Tying SK, Sinclair R, Thaçi D, et al. Tildrakizumab  
404 versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2):  
405 results from two randomised controlled, phase 3 trials. *Lancet (London, England)*.  
406 2017;390(10091):276-88.
- 407 43. Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A, et al. Efficacy and  
408 safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis:  
409 results from a randomized phase II study. *British Journal of Dermatology*. 2019;181(1):88-95.
- 410 44. Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients  
411 with Moderate to Severe Plaque Psoriasis: Eli Lilly and Company
- 412 [updated July 17, 2020]. Available from: [https://investor.lilly.com/news-releases/news-release-](https://investor.lilly.com/news-releases/news-release-details/lillys-mirikizumab-superior-cosentyxr-secukinumab-phase-3-study)  
413 [details/lillys-mirikizumab-superior-cosentyxr-secukinumab-phase-3-study](https://investor.lilly.com/news-releases/news-release-details/lillys-mirikizumab-superior-cosentyxr-secukinumab-phase-3-study).
- 414 45. Tzellos T, Kyrgidis A, Trigoni A, Zouboulis CC. Association of ustekinumab and  
415 briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and  
416 industry sponsored pooled analyses to date. *Dermatoendocrinol*. 2012;4(3):320-3.
- 417 46. Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC. Association of Ustekinumab vs TNF  
418 Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With  
419 Psoriasis or Psoriatic Arthritis. *JAMA Dermatology*. 2019;155(6):700-7.
- 420 47. Papp KA, Griffiths CEM, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term  
421 safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years  
422 of follow-up. *British Journal of Dermatology*. 2013;168(4):844-54.
- 423 48. Stelara (ustekinumab) [package insert]. Horsham, PA, Janssen Biotech, Inc., 2019.
- 424 49. Skyrizi (risankizumab-rzaa) [package insert], North Chicago, IL, AbbVie Inc., 2020.
- 425 50. Tremfya (guselkumab) [package insert], Horsham, PA, Janssen Biotech, Inc., 2019.
- 426 51. Ilumya (tildrakizumab-asmn) [package insert], Sharjah, U.A.E., Sun Pharma Global FZE,  
427 Inc., 2018
- 428 52. Dupixent (dupilumab) [package insert], Tarrytown, NY, Regeneron Pharmaceuticals,  
429 Inc., 2020.
- 430 53. Sawyer LM, Malotki K, Sabry-Grant C, Yasmeeen N, Wright E, Sohrt A, et al. Assessing  
431 the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-  
432 severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.  
433 *PLOS ONE*. 2019;14(8):e0220868.
- 434 54. Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-Term Efficacy and Safety of IL-17, IL-  
435 12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab,  
436 Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A

437 Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Journal of  
438 Immunology Research. 2019;2019:2546161.

439